Research on GLP-1 medications and body composition shows that patients who don't exercise while on semaglutide can lose a disproportionate amount of lean mass relative to fat
Her full endorsement of using Ozempic and Wegovy to treat obesity has opened the door for an important discussion about the use of these drugs in overweight and obese patients
These medications work by mimicking natural incretin hormones, which slow gastric emptying, enhance insulin secretion, suppress glucagon release, and reduce appetite through central nervous system pathways
Any combined use outside of an approved product or clinical trial would not be under standard medical monitoring
These criteria include type 2 diabetes diagnosis, cardiovascular disease or equivalent risk factors, HbA1c levels, and metabolic markersnot weight status
Why Professional Monitoring Matters GLP-1 therapy works best within a structured medical setting where your progress is tracked carefully